[SGLT2 inhibitors in acute decompensated heart failure, what do we know?]
A E LaptevaS N NasonovaIgor ZhirovSergey TereshchenkoPublished in: Terapevticheskii arkhiv (2022)
The current worldwide prevalence of heart failure is growing, while its combination with cardiovascular and other conditions determines a poor prognosis in these patients. Furthermore, acute decompensated heart failure is associated with a low survival rate mostly caused by target organ damage. The effects of early administration of SGLT2 inhibitors on renal function in patients with acute decompensated heart failure are being studied to determine the possibility of improving response to treatment, as well as partial or complete recovery of renal function. The goal of the review was to synthesize currently available evidence for the use of SGLT2 inhibitors in patients with acute decompensated heart failure. A systematic search for studies published from 2018 to 2021 and their analysis was carried out in the following databases: Web of Science, Scopus, PubMed/MEDLINE.
Keyphrases
- heart failure
- poor prognosis
- liver failure
- left ventricular
- acute heart failure
- cardiac resynchronization therapy
- end stage renal disease
- ejection fraction
- atrial fibrillation
- long non coding rna
- chronic kidney disease
- respiratory failure
- public health
- newly diagnosed
- risk factors
- systematic review
- hepatitis b virus
- oxidative stress
- drug induced
- prognostic factors
- patient reported outcomes
- aortic dissection
- big data
- extracorporeal membrane oxygenation
- mechanical ventilation